All In Biotech

Drug Trial Radar · NCT06699576

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

ARTEMIS-103: a Phase 1b, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination with Other Anti-cancer Agents in Patients with Bone and Soft Tissue Sarcoma.

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

448

Planned (sponsor's estimate)

Start

Dec 20, 2024

Primary completion

Dec 30, 2026

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced bone and soft tissue sarcoma.

Conditions

  • Osteosarcoma
  • Soft Tissue Sarcoma (STS)

Interventions

  • HS-20093Drug

    HS-20093: administered as an IV infusion

  • AnlotinibDrug

    Anlotinib: 12mg once daily (QD) orally

  • EpirubicinDrug

    Epirubicin: administered as an IV infusion

  • AdebrelimabDrug

    Adebrelimab: administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) for combination-treatmentsTime frame: Up to day 21 from the first dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.